Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma

被引:44
作者
Courts, Cornelius [1 ]
Montesinos-Rongen, Manuel [1 ]
Brunn, Anna [1 ]
Bug, Stefanie [2 ]
Siemer, Doerte [3 ]
Hans, Volkinar [4 ]
Bluemcke, Ingmar [5 ]
Klapper, Wolfram [6 ]
Schaller, Carlo [7 ]
Wiestler, Otmar D. [8 ]
Kueppers, Ralf [3 ]
Siebert, Reiner [2 ]
Deckert, Martina [1 ]
机构
[1] Univ Hosp Cologne, Dept Neuropathol, Cologne, Germany
[2] Univ Kiel, Inst Human Genet, Kiel, Germany
[3] Univ Duisburg Essen, Sch Med, Inst Cell Biol Tumor Res, Essen, Germany
[4] Evangel Krankenhaus, Dept Neuropathol, Bielefeld, Germany
[5] Univ Erlangen Nurnberg, Dept Neuropathol, Erlangen, Germany
[6] Univ Kiel, Inst Pathol, D-2300 Kiel, Germany
[7] Univ Hosp Bonn, Dept Neurosurg, Bonn, Germany
[8] German Canc Res Ctr, D-6900 Heidelberg, Germany
关键词
BLIMP1; central nervous system; diffuse large B-cell lymphoma; primary central nervous system lymphoma; PRDM1;
D O I
10.1097/NEN.0b013e31817dd02d
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Primary lympbomas of the CNS (PCNSLs) show molecular features of the late germinal center exit B-cell phenotype and are impaired in their terminal differentiation as indicated by a lack of immunoglobulin class switching. Because the positive regulatory domain I protein with ZNF domain (PRDM1/BLIMP1) is a master regulator of terminal B-cell differentiation into plasma cells, we investigated a series of 21 PCNSLs for the presence of mutations in the PRDM1 gene and alterations in the expression pattern of the PRDM1 protein. Direct sequencing of all coding exons of the PRDM1 gene identified deleterious mutations associated with abrogation of PRDM1 protein expression in 4 of 21 (19%) PCNSLs. Thus, similar to systemic diffuse large B-cell lymphomas, PRDM1 may be a tumor suppressor in some PCNSL and contribute to lymphomagenesis by impairing terminal differentiation.
引用
收藏
页码:720 / 727
页数:8
相关论文
共 24 条
[1]   Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo [J].
Angelin-Duclos, C ;
Cattoretti, G ;
Lin, KI ;
Calame, K .
JOURNAL OF IMMUNOLOGY, 2000, 165 (10) :5462-5471
[2]   Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma [J].
Brunn, Anna ;
Montesinos-Rongen, Manuel ;
Strack, Andreas ;
Reifenberger, Guido ;
Mawrin, Christian ;
Schaller, Carlo ;
Deckert, Martina .
ACTA NEUROPATHOLOGICA, 2007, 114 (03) :271-276
[3]   PRDM1/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage [J].
Cattoretti, G ;
Angelin-Duclos, C ;
Shaknovich, R ;
Zhou, HP ;
Wang, DO ;
Alobeid, B .
JOURNAL OF PATHOLOGY, 2005, 206 (01) :76-86
[4]  
Deckert M., 2007, WHO CLASSIFICATION T, P188
[5]  
Garcia JF, 2006, HAEMATOLOGICA, V91, P467
[6]   Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells [J].
Ghosh, N ;
Gyory, I ;
Wright, G ;
Wood, J ;
Wright, KL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (18) :15264-15268
[7]   Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines [J].
Györy, I ;
Fejér, G ;
Ghosh, N ;
Seto, E ;
Wright, KL .
JOURNAL OF IMMUNOLOGY, 2003, 170 (06) :3125-3133
[8]   Terminal differentiation of lymphocytes depends on Blimp-1 [J].
Kallies, Axel ;
Nutt, Stephen L. .
CURRENT OPINION IN IMMUNOLOGY, 2007, 19 (02) :156-162
[9]   IDENTIFICATION AND CHARACTERIZATION OF A NOVEL REPRESSOR OF INTERFERON-BETA GENE-EXPRESSION [J].
KELLER, AD ;
MANIATIS, T .
GENES & DEVELOPMENT, 1991, 5 (05) :868-879
[10]   Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method [J].
Livak, KJ ;
Schmittgen, TD .
METHODS, 2001, 25 (04) :402-408